Carfilzomib
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Carfilzomib: Proteasome inhibitor → CMM7 (CMM7)
One-Sentence Summary
Carfilzomib is a proteasome inhibitor marketed in Canada under the brand name KYPROLIS. The TxGNN model predicts it may be relevant for CMM7 (CMM7). This prediction has no clinical trials and no publications directly studying this disease, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | CMM7 (CMM7) |
| TxGNN Prediction Score | 0.9937 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for carfilzomib are not available in the data compiled for this report. Carfilzomib is generally understood to belong to the proteasome inhibitor class. Blocking the proteasome can cause proteotoxic stress and trigger cell death in cancer cells, which is the plausible basis for the model’s suggestion.
For CMM7, the link is a hypothesis only. It presumes that proteasome inhibition could affect melanoma-related cell survival pathways. No trial or publication addresses this specific entity, and the similarity between the original and predicted conditions has not been assessed. The prediction should be treated as a research question rather than a treatment signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for CMM7.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02459949 | KYPROLIS | Not recorded | Not recorded |
| 02451034 | KYPROLIS | Not recorded | Not recorded |
| 02459930 | KYPROLIS | Not recorded | Not recorded |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (proteasome inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; haematological parameters (CBC) and liver and renal function are commonly monitored for anticancer agents |
| Handling Protection | Please refer to the package insert and local cytotoxic drug handling regulations |
Safety Considerations
- Drug Interactions: 100 interactions were found in the interaction screening. Examples rated Major include oxandrolone, oxymetholone, stanozolol, deferiprone, samarium (153Sm) lexidronam, aminocaproic acid, avatrombopag, and several coagulation factor products (e.g., recombinant antihemophilic factor, von Willebrand factor, coagulation factor VIIa, coagulation factor X, human C1-esterase inhibitor, conestat alfa). Examples rated Moderate include metronidazole, naltrexone, rosuvastatin, simvastatin, tinidazole, palifermin, and strontium chloride Sr-89.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for CMM7 has no supporting trials or publications and no mechanistic data, so it remains a model-only hypothesis (L5).
To proceed, the following is needed:
- Confirmation of what CMM7 represents and its relationship to carfilzomib’s known activity
- Mechanism of action data for carfilzomib
- Package insert warnings and contraindications from Health Canada
- Preclinical studies directly in this disease before any clinical consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.